1. Home
  2. TSLX vs GLUE Comparison

TSLX vs GLUE Comparison

Compare TSLX & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$17.41

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$24.51

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSLX
GLUE
Founded
2010
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
TSLX
GLUE
Price
$17.41
$24.51
Analyst Decision
Buy
Strong Buy
Analyst Count
9
3
Target Price
$21.61
$32.00
AVG Volume (30 Days)
770.5K
1.5M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
10.82%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$123,672,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.20
$2.45
P/E Ratio
N/A
$72.42
Revenue Growth
N/A
63.54
52 Week Low
$16.04
$4.12
52 Week High
$25.17
$25.77

Technical Indicators

Market Signals
Indicator
TSLX
GLUE
Relative Strength Index (RSI) 53.96 78.97
Support Level $17.20 $17.35
Resistance Level $18.48 $25.56
Average True Range (ATR) 0.48 1.44
MACD 0.12 0.73
Stochastic Oscillator 67.49 93.63

Price Performance

Historical Comparison
TSLX
GLUE

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: